Zydus Lifesciences Gets Usfda Approval For Palbociclib Tablets

Top Stories

Company

L&T Partners with PS Technology to Revolutionise Railways

6 mins read. August 2, 2024 at 12:45 PM

Company

Jindal Saw Q1 FY24 PAT Rises 67% to Rs 441 Cr

4 mins read. August 2, 2024 at 12:41 PM

Company

Pfizer Q1 FY25 PAT Zooms 61% to Rs 151 Cr

4 mins read. August 2, 2024 at 12:36 PM

Stock chart

Zydus Lifesciences gets USFDA approval for Palbociclib tablets

ri-calendar-2-lineJun 30, 2023

By: BlinkX Research Team

FbkFbkTwitterTelegram

Zydus Lifesciences on Wednesday said in the filing that it has received tentative approval from the United States Food and Drug Administration (USFDA) for Palbociclib tablets, which are available in 75 mg, 100 mg, and 125 mg strengths.

The product will be manufactured at the group’s formulation manufacturing facility in SEZ, Ahmedabad, the company said in the filing.

Palbociclib is used to treat a certain type of breast cancer and its works by slowing or stopping the growth of cancer cells.

As per IQVIA MAT April 2023, Palbociclib had annual sales of $3.3 billion in the US.

The group now has 373 approvals and has so far filed over 442* ANDAs since the commencement of the filing process in FY2003-04.

 In the last week, Rising Sun Holdings Private Limited (the seller) and Mylab Discovery Solutions Private Limited reached an agreement with Zydus Animal Health and Investments Limited, a firm wholly controlled by Zydus Lifesciences.

This agreement states that Mylab will sell 6,506,500 equity shares, each with a face value of Rs 1, to Zydus Animal Health and Investments Limited. The agreed-upon total price for this transaction is Rs 106 crore or 6.5% of Mylab's total paid-up equity share capital.

Source: Media reports

Related News

News Thumbnail
Company

L&T Partners with PS Technology to Revolutionise Railways

6 mins read. August 2, 2024 at 12:45 PM

News Thumbnail
Company

Jindal Saw Q1 FY24 PAT Rises 67% to Rs 441 Cr

4 mins read. August 2, 2024 at 12:41 PM

News Thumbnail
Company

Pfizer Q1 FY25 PAT Zooms 61% to Rs 151 Cr

4 mins read. August 2, 2024 at 12:36 PM

News Thumbnail
Company

NBCC Arm Gets Two Construction Projects Worth Rs 443.61 Cr

4 mins read. August 2, 2024 at 12:33 PM

Related Blogs

Stock chartDemat Account

Biggest Winners and Losers in MSCI: Key Movers in Global Indices 2025

0 people read

3 mins read . Aug 20, 2025

Stock chartMutual Fund

What MF Big Boys Bought and Sold – Top Mutual Fund Stock Activity in 2025

0 people read

8 mins read . Aug 18, 2025

Download app

Access BlinkX
everywhere
across device

Join the Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions